Baudax Bio Reports First Quarter 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- US stocks set for lower open as Iran stalemate lifts oil, yields
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- Goldman Sachs to acquire real estate company LCN for up to $410M
Baudax Bio Inc. (BXRX) PT Lowered to $2 at Oppenheimer
May 6, 2021 6:43 AM EDTOppenheimer analyst Leland Gershell lowered the price target on Baudax Bio Inc. (NASDAQ: BXRX) to $2.00 (from $3.00) while maintaining an Outperform rating.
The analyst commented, "Reported 1Q21 net sales of just $0.2M as COVID-19 continues to drag on Anjeso's launch, with P&T committee... More
Baudax Bio (BXRX) Misses Q1 EPS by 8c
May 5, 2021 7:27 AM EDTBaudax Bio (NASDAQ: BXRX) reported Q1 EPS of ($0.27), $0.08 worse than the analyst estimate of ($0.19).
The first quarter has been busy and fruitful at Baudax. ANJESO sustained marked progress in the areas of new account wins, increasing units sold, reorder rates, and deepening usage... More
